NCT06655480View on ClinicalTrials.gov

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

December 31, 2026

Conditions
HFpEFLVDDMyocardial Fibrosis
Interventions
DRUG

[ARNI + SGLTi + AMR]

Empagliflozin 10mg tablet, Valsartan+Sacubitril 100-200-400 mg tablet, Finerenone 20-40 mg tablet

DRUG

[SGLTi + previously taken RAAS blocker]

Empagliflozin 10mg tablet, previously taken RAAS inhibitor

All Listed Sponsors
collaborator

Lomonosov Moscow State University Medical Center

UNKNOWN

lead

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

OTHER_GOV